Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling

Chen Xiaoping

Status: Completed

Conditions: Checkpoint Inhibitor; Adjuvant Immunotherapy; Hepatocellular Carcinoma

Treatments: Drug: Anti-PD-1 monoclonal antibody

Study type: Observational

Funder types: Other

Identifiers

NCT06298123

adjuvant-03

Details and patient eligibility

About

The aim of this study was to analyse the independent risk factors for hepatocellular carcinoma (HCC) patients undergoing adjuvant immunotherapy after liver resection surgery, and to develop a prognostic model based on these factors.

Full description

By retrospectively collecting patient data from a single centre of liver surgery at Tongji Hospital between February 2019 and February 2023, the study aimed to comprehensively evaluate patients' demographic characteristics, oncological parameters, surgical details and response to immunotherapy to identify the key factors affecting postoperative recurrence and survival.

Enrollment: 304 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HCC confirmed by pathologists
• Undergone a curative resection (R0)
• Aged 18-75 years
• No previous systematic treatment and locoregional therapy for HCC prior to randomization
• Absence of major macrovascular invasion
• No extrahepatic spread

Exclusion criteria

• Known fibrolamellar HCC, sarcomatoid HCC, mixed cholangiocarcinoma or recurrent HCC
• Any preoperative treatment for HCC including local and systemic therapy
• Unable to receive adjuvant therapy due to surgery-related complications, acute active infectious diseases, active or history of autoimmune disease, or immune deficiency
• incomplete clinical data